Topics

Companies Related to "Pilot And Phase 2 Study Of The Efficacy Of A Treatment Protocol With Dexamethasone Implant Loading Dose In Patients With Diabetic Macular Edema (LOADEX)" [Most Relevant Company Matches] [Advanced Search Results] RSS

23:00 EST 19th February 2020 | BioPortfolio

Here are the most relevant search results for "Pilot And Phase 2 Study Of The Efficacy Of A Treatment Protocol With Dexamethasone Implant Loading Dose In Patients With Diabetic Macular Edema (LOADEX)" found in our extensive corporate database of over 50,000 company records.

Showing "Pilot Phase Study Efficacy Treatment Protocol With Dexamethasone" Companies 1–25 of 5,100+

Extremely Relevant

Pharmacon Research GmbH

Pharmacon Research is an independent contract research organization (CRO) with headquarters in Berlin and clinical sites in Prague, Warsaw, Bratislava and Budapest. Founded in 1992 by the management of a successful Phase I unit, Pharmacon Research focuses on specific Phase I studies in patients and symptomatic subjects and on early Phase II studies (dose finding, proof of concept). Irrespective of...


Relevant

Vivus

VIVUS, Inc. is a pharmaceutical company dedicated to the development and commercialization of next-generation therapeutic products addressing obesity and sexual health. Analysts speculate that the potential market for obesity ranges from $5 billion to $10 billion annually, and the indications targeted by VIVUS' sexual health products each represent a projected market greater than $1 billion annual...

Tyrogenex

Tyrogenex is developing X-82, as a targeted therapeutic for ophthalmological diseases and solid tumors. Preliminary data from a phase 1/2 pilot study show that X-82 is well tolerated and did not exhibit any dose-limiting toxicity during the study.


Clinical Network Services (CNS)

Clinical Network Services (CNS) Pty Ltd is an Australian CRO, focused on providing full contract research organisational clinical trial services to the international healthcare community particularly during the early phase (Phase I and Phase II) clinical development of their products. CNS has established itself as Brisbane’s only headquartered Australian CRO working both nationally with dedicat...

NorthSea Therapeutics B.V.

NorthSea Therapeutics B.V.(NST) is a Dutch biotech company focused on developing structurally engineered fatty acids (‘SEFAs’) for the treatment of inflammatory, metabolic and liver diseases. NST licensed the rights to its lead compound icosabutate and a library of discovery- and pre-clinical-stage SEFAs from Pronova BioPharma Norge AS, which developed Omacor®, a blockbuster cardiova...

Ardea Biosciences, Inc.

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV). RDEA594, our lead product candidate for the treatment of hyperuricemia and gout, is a selective URAT1 transporter inhibitor in Phase 2 clinical development. Our next-generation URAT1 inhib...

Richmond Pharmacology Ltd

Our goal is to deliver full service Early Phase clinical solutions swiftly, efficiently, and to the highest clinical standard. Our integrated set-up is designed to manage your Early Phase study within the controlled environment of Phase I. We compliment this through our out-patient facilities offering flexibility through the Phases in clinical trials.“Richmond Pharmacology is the UK's only Early...

Isolagen

Isolagen® Inc., a biotechnology company focused on developing emergent, novel skin and tissue rejuvenation technology for application in certain aesthetic and therapeutic markets. I am pleased to lead Isolagen Inc. as Chairman and Chief Executive Officer. Previously, I served as Chairman, President and CEO of Inamed Corporation, a leading specialty aesthetics company acquired by Allergan Inc. ...

Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, inflammatory disease and sexual dysfunction. The Company's lead drug candidate, Piclidenoson, is scheduled to enter Phase III trials in 2...

Northwest Kinetics Incorporated

Northwest Kinetics is an independent research facility which specializes in Phase I and Phase II clinical pharmaceutical studies. Northwest Kinetics provides a full range of services for both short and long-term Phase I and II trials. Our services can include review of protocol design, pharmacokinetic consultation, patient recruitment, study execution, data management and record keeping, and repor...

Allegro Ophthalmics, LLC,

Allegro Ophthalmics, LLC is a privately held biopharmaceutical company focused on the development of novel anti-integrin therapies for the treatment of ocular diseases. Allegro’s lead investigational drug risuteganib (Luminate®) successfully completed two Phase 2 diabetic macular edema (DME) studies and is currently being evaluated in a U.S. ...

Adamis Pharmaceuticals Corporation

La Jolla Pharmaceutical Company is a biopharmaceutical company. La Jolla had historically focused substantially all of its research, development and clinical efforts and financial resources toward the development of its Riquent® (abetimus sodium) product candidate, as a treatment for patients with lupus. In February 2009, La Jolla announced that an inde...

TOPICA Pharmaceuticals, Inc.

TOPICA Pharmaceuticals, Inc. is a privately held clinical research stage pharmaceutical company focused on developing luliconazole for the treatment of onychomycosis, or fungal infections of the nail. The company is focused on conducting the Phase 2b/3 SOLUTION Study, a robust dose finding and proof of efficacy trial with luliconazole in onychomycosis with...

BioTechNews Denmark

TopoTarget and CuraGen Announce Initiation of NCI-sponsored Phase II Clinical Trial with PXD101 for MesotheliomaTopoTarget A/S and CuraGen Corporation announced today the initiation of patient dosing in a Phase II clinical trial evaluating the activity of PXD101, a small molecule histone deacetylase (HDAC) inhibitor, for the treatment of mesothelioma. This trial is being sponsored by the National ...

InnoPharm Limited

InnoPharm Ltd. is an independent Russian domestic contract research organization providing Phase II-IV clinical trials support. InnoPharm was established in 1991 and operates in Russia (mainly its European part), Ukraine and Belarus. We also perform data management and statistical processing of data generated in clinical studies conducted all over the world and organize regular and ad-hoc GCP semi...

RTL

° Phase I through Phase IV clinical trials for the development of prescription and OTC drugs, and dental and oral health products. ° New product development to test the relative safety and efficacy of experimental products or product ingredients. ° Testing to substantiate advertising claims.° Our Clinical Research Organization consists of a team of professionals trained in all phases of clinic...

Neuro-Hitech

Neuro-Hitech is focused specifically on the development and commercialization of next-generation therapies against proven targets for neurodegenerative diseases. The company’s signature offering, Huperzine A is being tested for efficacy in the treatment of Alzheimer's disease and the company has plans to study other degenerative disorders such as vascular dementia, mild cognitive impairment and ...

BioLineRx Ltd. and Compugen Ltd.

BioLineRx Ltd. is a publicly-traded biopharmaceutical development company. It is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. BioLineRx’s current portfolio consists of five clinical stage candidates: BL-1020 for schizophrenia has commenced a Phase II/III study; BL-1040 for...

NPS Pharmaceuticals, Inc.

NPS Pharmaceuticals is developing new treatment options for patients with rare gastrointestinal and endocrine disorders. The company is currently advancing two Phase 3 registration programs. Teduglutide, a proprietary analog of GLP-2, is being evaluated as GATTEX® in a Phase 3 registration study known as STEPS for intestinal failure associated with shor...

Genosco

Located in Cambridge, MA, Genosco is a clinical-stage biotechnology company led by CEO, Dr. Jong Sung (John) Koh, focusing on developing and commercializing novel immunology and oncology treatments to improve the lives of patients. Genosco’s core competence comes from its expertise in generating selective kinase inhibitors that include candidates that ...

Shape Pharmaceuticals, Inc.

Shape Pharmaceuticals, Inc. is developing SHP-141, a novel, topical, “soft-drug” HDAC inhibitor for the treatment of patients with cutaneous T cell lymphoma (CTCL) and psoriasis. Shape has an ongoing Phase 1b clinical study in CTCL patients and has completed a Phase 1b clinical study in psoriasis patients. The development of SHP-141 is being supp...

Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. (NASDAQ-PPHM) is a clinical stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection. The Company is advancing three separate clinical programs with its lead product candidates bavituximab and Cotara®. Bavituximab and Cotara are both in Phase II clinical studies for the treatment o...

Hallux Incorporated

Hallux is developing an investigational micro-insert for subungual delivery and treatment of distal lateral subungual onychomycosis. The dosage form is biodegradable and delivers high concentrations of terbinafine hydrochloride directly and selectively to the site of infection over a period of time. Results from pilot studies are encouraging and suggest th...

BioClin Therapeutics, Inc.

BioClin Therapeutics, Inc. is a privately-held clinical stage drug development company developing biologics to address medical conditions in areas of high unmet need. The company’s lead candidate is B-701, a potential first-in-class human monoclonal antibody targeting FGFR3 (fibroblast growth factor receptor 3). B-701 is currently being evaluated in t...

Favrille

We are a biopharmaceutical company focused on the development and commercialization of patient-specific immunotherapies for the treatment of cancer and other diseases of the immune system. We own a proprietary technology that enables us to efficiently develop and manufacture active immunotherapy products designed to stimulate a patient's own immune system to mount a specific and sustained response...


More From BioPortfolio on "Pilot And Phase 2 Study Of The Efficacy Of A Treatment Protocol With Dexamethasone Implant Loading Dose In Patients With Diabetic Macular Edema (LOADEX)"

Quick Search

Corporate Database Quicklinks